- Recombinant Proteins
- Accession Number
Proteins prepared by recombinant DNA technology.
Drug Drug Description Denileukin diftitox A recombinant cytotoxic protein based on a combination of diphtheria toxin fragments and interleukin-2 used to treat cutaneous T-cell lymphoma by targeting the interleukin-2 receptor. Rasburicase A recombinant form of urate-oxidase enzyme used to treat hyperuricemia following chemotherapy for leukemias and non-Hodgkin's lymphoma. Imiglucerase A form of recombinant human beta-glucocerebrosidase enzyme used to replace the deficient endogenous enzyme in the treatment of Gaucher disease. Alglucerase A form of recombinant beta-glucocerebrosidase enzyme used to replace the deficient endogenous enzyme in the treatment of Gaucher disease. Alefacept A recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis. Desmoteplase Investigated for use/treatment in cerebral ischemia and strokes. Oportuzumab monatox Investigated for use/treatment in bladder cancer and head and neck cancer. Romiplostim A fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP). Praconase Investigated for use/treatment in spinal cord injuries. Maxy-G34 Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics. PRO-542 Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications. GI-5005 Investigated for use/treatment in hepatitis (viral, C). Rilonacept An IL-1 inhibitor used to treat cryopyrin-associated periodic syndrome, a rare hereditary inflammatory disorder. Atacicept Investigated for use/treatment in autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, multiple myeloma, lymphoma (non-hodgkin's), and leukemia (lymphoid). Onercept Investigated for use/treatment in psoriasis and psoriatic disorders and crohn's disease. Baminercept Investigated for use/treatment in rheumatoid arthritis. Pegsunercept Investigated for use/treatment in rheumatoid arthritis. Taliglucerase alfa A hydrolytic lysosomal glucocerebroside specific enzyme, used for long term enzyme replacement therapy in patients with Type 1 Gaucher disease. Aflibercept A vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy. Albiglutide A GLP-1 agonist used to manage type 2 diabetes mellitus. Dulaglutide A GLP-1 agonist used to manage type 2 diabetes mellitus. Elosulfase alfa A lysosomal glycosaminoglycan (GAG)-specific enzyme indicated as an enzyme replacement therapy for Mucopolysaccharidosis type IV A. Corifollitropin alfa A FSH analogue indicated for Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program. Asfotase alfa An enzyme replacement therapy used for the treatment of perinatal/infantile and juvenile onset hypophosphatasia (HPP). Turoctocog alfa An antihemorrhagic agent used for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency). Vonapanitase Vonapanitase is under investigation for the treatment of Chronic Kidney Disease. Trebananib Trebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon... Sotatercept Sotatercept has been used in trials studying the supportive care and treatment of Anemia, Leukemia, Solid Tumors, Bladder Cancer, and multiple myeloma, among others. Vanutide cridificar Vanutide cridificar has been investigated for the treatment of Alzheimer Disease. Blisibimod Blisibimod has been used in trials studying the treatment of IgA Nephropathy, Microscopic Polyangiitis, Systemic Lupus Erythematosus, and Granulomatosis With Polyangiitis. Dulanermin Dulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma, and Metastatic Colorectal Cancer. Conbercept Conbercept has been investigated for the basic science of Age-related Macular Degeneration. Balugrastim Balugrastim has been used in trials studying the treatment of Solid Tumors. Moroctocog alfa A recombinant Factor VIII used to treat hemophilia A to control bleeding. Antihemophilic factor (recombinant), PEGylated For the management of hemophilia A (congenital factor VIII deficiency) [FDA label], . This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older)... Elapegademase A recombinant adenosine deaminase used to treat adenosine deaminase severe combined immune deficiency. Turoctocog alfa pegol Turoctocog alfa pegol (N8-GP) is indicated for use in adults and children of all ages with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis in reducing the frequency of... Dalantercept Dalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma). Ipafricept Ipafricept is under investigation in clinical trial NCT01608867 (A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors). Leridistim Leridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia). Asunercept Asunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme). DAS-181 DAS-181 is under investigation in clinical trial NCT00527865 (Single Dose Escalating Study of DAS181 in Adults). Valanafusp alfa Valanafusp alfa is under investigation in clinical trial NCT03071341 (Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I). ALT-801 ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia). Cintredekin besudotox Investigated for use/treatment in brain cancer. Eftrenonacog alfa A recombinant Factor IX used to treat and prevent bleeding in hemophilia B. Endostar Endostar is under investigation for the treatment of Nasopharyngeal Carcinoma. Endostar has been investigated for the treatment of Non-small Cell Lung Cancer. Abicipar Pegol Abicipar Pegol has been used in trials studying the treatment of Macular Edema and Macular Degeneration. Luspatercept An erythroid maturation agent used to treat anemia secondary to beta thalassemia in patients requiring regular red blood cell transfusions. Albusomatropin Albusomatropin has been used in trials studying the treatment of Growth Hormone-Deficiency and Growth Hormone Deficiency. Albutrepenonacog alfa A recombinant Factor IX fused to recombinant human albumin used to treat hemophilia B. Tagraxofusp A CD123-directed cytotoxin used to treat plasmacytoid dendritic cell neoplasm. Pegilodecakin Pegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer). Talactoferrin alfa Investigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers. Bizalimogene ralaplasmid Bizalimogene ralaplasmid is under investigation in clinical trial NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 And/or HPV-18 Related Anal or Anal/peri-anal, High Grade... Otlertuzumab Otlertuzumab is under investigation in clinical trial NCT01188681 (Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia). Tengonermin Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide....
- Drugs & Drug Targets